Informações:
Falhas:
ID
41426
Descrição
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01241708
Link
https://clinicaltrials.gov/show/NCT01241708
Palavras-chave
Versões (3)
- 17/01/2019 17/01/2019 -
- 01/10/2020 01/10/2020 -
- 05/10/2020 05/10/2020 - Sarah Riepenhausen
Titular dos direitos
Hackensack Meridian Health
Transferido a
5 de outubro de 2020
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Multiple Myeloma NCT01241708
Eligibility Multiple Myeloma NCT01241708
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Myeloma NCT01241708
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Multiple myeloma (Durie-Salmon or ISS), recent initiation of systemic therapy
Item
confirmed diagnosis of multiple myeloma with either durie-salmon stage i, ii, or iii or iss stage i, ii or iii, less than 12 months since initiation of systemic therapy
boolean
C0026764 (UMLS CUI [1])
C4528204 (UMLS CUI [2])
C2346508 (UMLS CUI [3])
C1704686 (UMLS CUI [4,1])
C1515119 (UMLS CUI [4,2])
C0026764 (UMLS CUI [4,3])
C0332185 (UMLS CUI [4,4])
C4528204 (UMLS CUI [2])
C2346508 (UMLS CUI [3])
C1704686 (UMLS CUI [4,1])
C1515119 (UMLS CUI [4,2])
C0026764 (UMLS CUI [4,3])
C0332185 (UMLS CUI [4,4])
CD34+ cells in cryopreservation appropriate for tandem transplants
Item
≥8x106 cd34+cells/kg available in cryopreservation in aliquots appropriate for tandem transplants
boolean
C0470187 (UMLS CUI [1,1])
C0882849 (UMLS CUI [1,2])
C0010405 (UMLS CUI [1,3])
C0205173 (UMLS CUI [1,4])
C1504389 (UMLS CUI [1,5])
C0882849 (UMLS CUI [1,2])
C0010405 (UMLS CUI [1,3])
C0205173 (UMLS CUI [1,4])
C1504389 (UMLS CUI [1,5])
Age at time of transplantation
Item
age: 18-75 years at time of transplantation
boolean
C0001779 (UMLS CUI [1,1])
C2348792 (UMLS CUI [1,2])
C0040732 (UMLS CUI [1,3])
C2348792 (UMLS CUI [1,2])
C0040732 (UMLS CUI [1,3])
kps
Item
kps 70-100%
boolean
C0206065 (UMLS CUI [1])
Recovery from complications of prior therapies
Item
recovery from complications of prior therapies
boolean
C1514463 (UMLS CUI [1,1])
C0009566 (UMLS CUI [1,2])
C1115804 (UMLS CUI [1,3])
C0009566 (UMLS CUI [1,2])
C1115804 (UMLS CUI [1,3])
Gender
Item
gender: there is no gender restriction
boolean
C0079399 (UMLS CUI [1])
Other diagnosis than multiple myeloma
Item
diagnosis other than multiple myeloma
boolean
C0011900 (UMLS CUI [1,1])
C0332300 (UMLS CUI [1,2])
C0026764 (UMLS CUI [1,3])
C0332300 (UMLS CUI [1,2])
C0026764 (UMLS CUI [1,3])
Chemotherapy or radiotherapy
Item
chemotherapy or radiotherapy within 8 days of initiating treatment in this study
boolean
C0392920 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
C1301732 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
Prior autologous or allogeneic transplantation
Item
prior autologous or allogeneic transplantation (except as enrolled into this study)
boolean
C1514463 (UMLS CUI [1,1])
C1831743 (UMLS CUI [1,2])
C1514463 (UMLS CUI [2,1])
C0149615 (UMLS CUI [2,2])
C1831743 (UMLS CUI [1,2])
C1514463 (UMLS CUI [2,1])
C0149615 (UMLS CUI [2,2])
Uncontrolled bacterial, viral, fungal or parasitic infections
Item
uncontrolled bacterial, viral, fungal or parasitic infections
boolean
C0004623 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0042769 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0026946 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0747256 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0205318 (UMLS CUI [1,2])
C0042769 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0026946 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0747256 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
Sem comentários